TriangleNCT02094573 · CITED IN SOURCE DOCUMENTS
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2021-03-15
The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of brigatinib (AP26113) in participants with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with crizotinib.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Confirmed Objective Response Rate (ORR) as Assessed by Investigator
Confirmed Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC)
Confirmed Intracranial Central Nervous System Objective Response Rate (CNS ORR) in Participants With Measurable Active Brain Metastases
Confirmed Intracranial Central Nervous System Objective Response Rate (CNS ORR) in Participants With Only Non-measurable Active Brain Metastases
Intracranial CNS Progression Free Survival (PFS) in Participants With Active Brain Metastases
Time to Response
Duration of Response
Time on Treatment
Disease Control Rate (DCR)
Progression Free Survival (PFS)
Overall Survival (OS)
Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE)
Pre-dose Brigatinib Plasma Concentration
Patient-reported Symptoms Global Health Status/Quality of Life (QoL) Scores
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Have histologically or cytologically confirmed locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) that is anaplastic lymphoma kinase (ALK+). 2. Must meet one of the following two criteria: 1. Have documented ALK rearrangement by a positive result from the Vysis® ALK Break-Apart fluorescence in situ hybridization (FISH) Probe Kit; or 2. Have documented ALK positivity by a different test and tissue available for the Vysis® FISH test. Tissue should be derived preferably from a biopsy taken after progression with crizotinib. If such a sample is not available, testing may be performed with archived tumor tissue. 3. Had progressive disease while on crizotinib, as assessed by the investigator or treating physician. 4. Have at least 1 measurable lesion per RECIST v1.1. Note: Previously irradiated lesions may not be used for target lesions, unless there is unambiguous radiological progression after radiotherapy. Brain lesions may not be used as target lesions if they were: 1) previously treated with whole brain radiation therapy (WBRT) within 3 months, or 2) previously treated by stereotactic radiosurgery (SRS) or surgical resection. 5. Recovered from toxicities related to prior anticancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v4.0) grade ≤2. 6. Are a male or female participants ≥18 years old. 7. Have a life expectancy ≥3 months. 8. Have adequate organ and hematologic function, as determined by: 1. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x upper limit of normal (ULN; ≤5 x ULN is acceptable if liver metastases are present) 2. Total serum bilirubin ≤1.5 x ULN (\<3.0 x ULN for participants with Gilbert syndrome) 3. Serum creatinine ≤1.5 x ULN 4. Serum lipase/amylase ≤1.5 x ULN 5. Absolute neutrophil count (ANC) ≥1500/µL 6. Platelets ≥75000/µL 7. Hemoglobin ≥10 g/dL 9. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2. 10. Have normal QT interval on screening electrocardiogram (ECG) evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 ms in males or ≤470 ms in females. 11. For female participants of childbearing potential, a negative pregnancy test must be documented prior to enrollment. 12. Female and male participants who are fertile must agree to use a highly effective form of contraception with their sexual partners throughout study participation. 13. Must provide a signed and dated informed consent indicating that the participants has been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating. 14. Have the willingness and ability to comply with scheduled visits and study procedures. Exclusion Criteria: 1. Received any prior ALK-targeted TKI other than crizotinib. 2. Received crizotinib within 3 days of the first dose of brigatinib (Day 1, Cycle 1). 3. Received cytotoxic chemotherapy, investigational agents, or radiation within 14 days, except SRS or stereotactic body radiosurgery. 4. Received monoclonal antibodies or had major surgery within 30 days of the first dose of brigatinib (Day 1, Cycle 1). 5. Have been diagnosed with another primary malignancy within the past 3 years (except for adequately treated non-melanoma skin cancer, cervical cancer in situ, or prostate cancer, which are allowed within 3 years). 6. Have symptomatic CNS metastases that are neurologically unstable or require an increasing dose of corticosteroids. 7. Have current spinal cord compression. 8. Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: 1. Myocardial infarction (MI) within 6 months prior to the first dose of brigatinib 2. Unstable angina within 6 months prior to first dose 3. Congestive heart failure (CHF) within 6 months prior to first dose 4. History of clinically significant (as determined by the treating physician) atrial arrhythmia 5. Any history of ventricular arrhythmia 6. Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose 9. Have a history or the presence of pulmonary interstitial disease or drug-related pneumonitis. 10. Have an ongoing or active infection. The requirement for intravenous (IV) antibiotics is considered active infection. 11. Have a known history of human immunodeficiency virus (HIV). Testing is not required in the absence of history. 12. Have a history of or active significant gastrointestinal (GI) bleeding within 3 months of the first dose of brigatinib. 13. Have a known or suspected hypersensitivity to brigatinib or its excipients. 14. Have malabsorption syndrome or other GI illness that could affect oral absorption of the study drug. 15. Have any condition or illness that, in the opinion of the investigator, would compromise participants safety or interfere with evaluation of the drug study. 16. Be pregnant or breastfeeding.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).
- intervention Names
- Drug: Brigatinib
- label
- Brigatinib 90 mg
- type
- EXPERIMENTAL
- description
- Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).
- intervention Names
- Drug: Brigatinib
- label
- Brigatinib 90 mg - 180 mg
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Brigatinib 90 mg
- Brigatinib 90 mg - 180 mg
- description
- Brigatinib tablets
- name
- Brigatinib
- other Names
- AP26113
- ALUNBRIG™
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 222
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- ORR assessed by the investigator, was defined as percentage of the participants with confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) v1.1 (confirmed ≥4 weeks after initial response), after initiation of study treatment. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and norrmalization of tumor marker level. PR: at least 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline sum diameters. The exact 2-sided 97.5% confidence interval was calculated. The treatment regimen was considered to have achieved the primary objective when lower bound of the 97.5% confidence interval for ORR assessed by investigator is greater than 20%.
- measure
- Confirmed Objective Response Rate (ORR) as Assessed by Investigator
- time Frame
- Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered Cycle of 28-days) through 15 Cycles and every 3 Cycles thereafter until disease progression or up to end of the study (approximately up to 69 months)
- secondary Outcomes
- description
- ORR assessed by the IRC, was defined as the percentage of the participants with CR or PR according to RECIST v1.1 (confirmed ≥4 weeks after initial response), after the initiation of study treatment. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in theSLD of target lesions, taking as reference the baseline sum diameters. The exact 2-sided 95% confidence interval was calculated.
- measure
- Confirmed Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC)
- time Frame
- Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered Cycle of 28-days) through 15 Cycles and every 3 Cycles thereafter until disease progression or up to end of the study (approximately up to 69 months)
- description
- Confirmed intracranial CNS ORR was defined as the percentage of the participants with CR or PR in the intracranial CNS per modification of RECIST v1.1 as evaluated by IRC after the initiation of study drug. Confirmed responses were those that persisted on repeat imaging 4 weeks or more after initial response. CR for target lesion: disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis). CR for non-target lesion: disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.
- measure
- Confirmed Intracranial Central Nervous System Objective Response Rate (CNS ORR) in Participants With Measurable Active Brain Metastases
- time Frame
- Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered Cycle of 28-days) through 15 Cycles and every 3 Cycles thereafter until disease progression or approximately up to 29 months
- description
- Confirmed intracranial CNS ORR is defined as the percentage of the participants with CR or PR in the intracranial CNS per modification of RECIST v1.1 as evaluated by IRC after the initiation of study drug. Confirmed responses were those that persisted on repeat imaging 4 weeks or more after initial response. CR for target lesion: disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis). CR for non-target lesion: disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.
- measure
- Confirmed Intracranial Central Nervous System Objective Response Rate (CNS ORR) in Participants With Only Non-measurable Active Brain Metastases
- time Frame
- Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered Cycle of 28-days) through 15 Cycles and every 3 Cycles thereafter until disease progression or approximately up to 29 months
- description
- Intracranial CNS PFS as evaluated by IRC is defined as the time interval from the date of the first dose of the study drug until the first date at which intracranial CNS disease progression, an increase of 20% or more in the sum of diameters of intracranial CNS target lesions, unequivocal progression of non-target lesions, or the appearance of new lesions in the intracranial CNS, was objectively documented by a scan, or death due to any cause, whichever occurred first. The analysis was based on the Kaplan-Meier (KM) Estimates.
- measure
- Intracranial CNS Progression Free Survival (PFS) in Participants With Active Brain Metastases
- time Frame
- Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered Cycle of 28-days) through 15 Cycles and every 3 Cycles thereafter until disease progression or approximately up to 29 months
- description
- Time to response was defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.
- measure
- Time to Response
- time Frame
- Up to approximately 69 months
- description
- Duration of response was defined as the time interval from the time that the measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that the progressive disease is objectively documented or death. Patients without progressive disease or death were censored at the last valid response assessment. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters. The analysis was based on the Kaplan-Meier (KM) Estimates.
- measure
- Duration of Response
- time Frame
- Up to approximately 69 months
- description
- Time on treatment was defined as the time from the first to the last dose of study drug. For participants who have not discontinued, time on treatment was censored as of the last dose of the study drug.
- measure
- Time on Treatment
- time Frame
- Up to approximately 69 months
- description
- DCR was defined as the percentage of randomized participants who were confirmed to have achieved CR or PR or have a best overall response as stable disease (SD) for 6 weeks or more after initiation of the study drug. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD was defined as at least a 20% increase in the sum of diameters of target lesions.
- measure
- Disease Control Rate (DCR)
- time Frame
- Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered Cycle of 28-days) through 15 Cycles and every 3 Cycles thereafter until disease progression or up to end of the study (approximately up to 69 months)
- description
- PFS was defined as the time interval from the date of the first dose of the study treatment until the first date at which disease progression is objectively documented, or death due to any cause, whichever occurs first. Disease progression for target lesion: SLD increased by at least 20% from the smallest value on study (including Baseline, if that is the smallest) and SLD must also demonstrate an absolute increase of at least 5 mm or development of any new lesion. Disease progression for non-target lesion: Unequivocal progression of existing non-target lesions. (Subjective judgment by experienced reader). The analysis was based on the Kaplan-Meier (KM) Estimates.
- measure
- Progression Free Survival (PFS)
- time Frame
- Up to approximately 69 months
- description
- OS is defined as the time interval from the date of the first dose of the study treatment until death due to any cause. Intracranial OS was calculated by Kaplan-Meier estimation.
- measure
- Overall Survival (OS)
- time Frame
- Up to approximately 69 months
- description
- An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.
- measure
- Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE)
- time Frame
- From first dose of study drug up to 30 days following the last dose of study drug (approximately up to 69 months)
- measure
- Pre-dose Brigatinib Plasma Concentration
- time Frame
- Day 1 Cycles 2, 3, 4 and 5 (each Cycle of 28-days) pre-dose
Full study description
- brief Summary
- The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of brigatinib (AP26113) in participants with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with crizotinib.
- detailed Description
- The drug being tested in this study is called brigatinib (AP26113). Brigatinib was tested to treat people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or were intolerant to crizotinib. This study looked at the efficacy of brigatinib. The study enrolled 222 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups: * Brigatinib 90 mg * Brigatinib 90 mg -180 mg All participants were asked to take a tablet, orally once daily until disease progression or intolerable toxicity. Participants in Brigatinib 90 mg - 180 mg received 180 mg with a 7-day lead-in at 90 mg. This multi-center trial was conducted worldwide. The overall time to participate in this study is up to 3 years. Participants will make multiple visits to the clinic, and 3 months after the End-of-Treatment visit. Follow-up is intended to continue for 2 years after the last participants was enrolled into the study.
Source references
- references
- citation
- Kawata AK, Lenderking WR, Eseyin OR, Kerstein D, Huang J, Huang H, Zhang P, Lin HM. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study. J Med Econ. 2019 Sep;22(9):924-935. doi: 10.1080/13696998.2019.1624080. Epub 2019 Jun 25.
- pmid
- 31125274
- type
- DERIVED
- citation
- Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. 2018 Sep 10;36(26):2693-2701. doi: 10.1200/JCO.2017.77.5841. Epub 2018 May 16.
- pmid
- 29768119
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-5d5de0d253a31cff0f86
- requested nct id
- NCT02094573
- primary nct id
- NCT02094573
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
- payload sha256
- 008ce3f0fe9372748fc2366cedfb2d47325eb42e2ce972bd9c0818e73d98a1a4
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-5d5de0d253a31cff0f86
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02094573
- occurrences
- context exact
- 2" tabindex="-1">Evidence (brigatinib):</p> <div class="pdq-content-list"><ol id="_485533"><li>A phase II, open-label trial (<a href="/clinicaltrials/NCT02094573">NCT02094573</a>) enrolled 222 patients with <em class="gene-name">ALK</em>-translocated locally advanced or metastatic NSCLC who had disease progression after
- end
- 519629
- exact text
- NCT02094573
- start
- 519618
- context exact
- -1">Evidence (brigatinib):</p> <div class="pdq-content-list"><ol id="_485533"><li>A phase II, open-label trial (<a href="/clinicaltrials/NCT02094573">NCT02094573</a>) enrolled 222 patients with <em class="gene-name">ALK</em>-translocated locally advanced or metastatic NSCLC who had disease progression after crizotinib t
- end
- 519642
- exact text
- NCT02094573
- start
- 519631
- context exact
- tabindex="-1">Evidence (brigatinib):</p> <div class="pdq-content-list"><ol id="_485378"><li> A phase II open-label trial (<a href="/clinicaltrials/NCT02094573">NCT02094573</a>) enrolled 222 patients with <em class="gene-name">ALK</em>-translocated locally advanced or metastatic NSCLC who had disease progression after
- end
- 708100
- exact text
- NCT02094573
- start
- 708089
- context exact
- ">Evidence (brigatinib):</p> <div class="pdq-content-list"><ol id="_485378"><li> A phase II open-label trial (<a href="/clinicaltrials/NCT02094573">NCT02094573</a>) enrolled 222 patients with <em class="gene-name">ALK</em>-translocated locally advanced or metastatic NSCLC who had disease progression after crizotinib t
- end
- 708113
- exact text
- NCT02094573
- start
- 708102
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/11a3437f29dc92742e.html
- source file sha256
- 6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:59.782436+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 96af5062fe49c6481bdc1ef6946e69939f30c810b02e368845c837ccf6c0977c
- source title
- Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: May 15, 2025
- datetime
- 2025-05-15T12:00:00Z
- display
- May 15, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-9316ec96a2d62db3d951
- requested nct id
- NCT02094573
- primary nct id
- NCT02094573
- source kind
- fda_spl_label
- source record id
- 176eb255-05c0-4cfc-874f-1fb57136d34d
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- a634c10112608d897eecc473665904c8221486bbb3dd65378fa109093fb50be4
- payload
- application numbers
- NDA208772
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-9316ec96a2d62db3d951
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02094573
- occurrences
- context exact
- ve Advanced or Metastatic NSCLC Previously Treated with Crizotinib The efficacy of ALUNBRIG was demonstrated in a two-arm, open-label, multicenter trial (ALTA, NCT02094573) in adult patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who had progressed on crizotinib. The study required pat
- end
- 5118
- exact text
- NCT02094573
- start
- 5107
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/76/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 176eb255-05c0-4cfc-874f-1fb57136d34d
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- fbe0b16afafb0be49ec5ea4cc02c15f7e52b8d1e3e41d7f70290af91389fd8c6
- spl effective time
- 20260112
- spl set id
- 0fe9ff20-d402-41f3-bc1e-7002ea7007db
Preserved source evidence · Not medical advice